DexCom, Inc. (DXCM) Earnings Per Share (EPS): 2.34
Is DexCom, Inc.’s earnings per share (EPS) high or low?
DexCom, Inc.'s earnings per share (EPS) of 2.34 is 80% above its 5-year average of 1.30, near the high end of its 5-year range (0.56–2.34).
As of Thursday, June 18, 2026. 30.00% above its 12-month average of 1.80.
DXCM Earnings Per Share (EPS) Chart
DXCM Average Earnings Per Share (EPS) Chart
DXCM Current vs Average Earnings Per Share (EPS) Chart
DXCM Earnings Per Share (EPS) Metrics
EARNINGS PER SHARE (EPS)
2.34
EARNINGS PER SHARE (EPS) AVG TTM
1.80
EARNINGS PER SHARE (EPS) AVG 3Y
1.48
EARNINGS PER SHARE (EPS) AVG 5Y
1.30
EARNINGS PER SHARE (EPS) AVG 10Y
0.65
EARNINGS PER SHARE (EPS) AVG 15Y
0.40
EARNINGS PER SHARE (EPS) AVG 20Y
0.11
CURRENT VS TTM AVG
+30.00%
CURRENT VS 3Y AVG
+58.11%
CURRENT VS 5Y AVG
+80.23%
CURRENT VS 10Y AVG
+258.50%
CURRENT VS 15Y AVG
+485.41%
CURRENT VS 20Y AVG
+1993.49%
DXCM Competitors' Earnings Per Share (EPS)
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DexCom, Inc. (DXCM) | $27.49B | 2.34 | 1.80 | 1.48 | 1.30 |
| IQVIA Holdings Inc. (IQV)vs › | $28.48B | 8.07 | 7.74 | 7.17 | 5.87 |
| Veeva Systems Inc. (VEEV)vs › | $25.96B | 5.61 | 4.98 | 4.09 | 3.61 |
| Biogen Inc. (BIIB)vs › | $29.33B | 9.34 | 10.02 | 12.26 | 14.06 |
| Centene Corporation (CNC)vs › | $29.94B | -13.14 | -3.64 | -0.05 | 0.88 |
| Moderna, Inc. (MRNA)vs › | $24.52B | -8.15 | -8.27 | -1.90 | 3.46 |
| Medline Inc. (MDLN)vs › | $30.65B | 1.21 | 1.48 | 0.80 | 0.80 |
| Waters Corporation (WAT)vs › | $23.53B | 7.87 | 10.78 | 11.05 | 10.65 |
| United Therapeutics Corporation (UTHR)vs › | $23.41B | 27.05 | 28.29 | 23.40 | 19.31 |
| BioNTech SE (BNTX)vs › | $23.27B | -5.94 | -4.08 | 9.21 | 14.48 |
EPS Comparison
Trailing EPS (TTM)
$2.34
Forward EPS (Est.)
$3.09
P/E Ratio
30.4
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
- Directly impacts stock valuation through P/E ratio
- Used to calculate dividend coverage and payout ratios
- Enables comparison across companies of different sizes
- Growth in EPS often correlates with stock price appreciation
DexCom, Inc. Earnings Per Share (EPS) Formula & Definition
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. Earnings Per Share (EPS) FAQ
- What is the earnings per share (EPS) for DexCom, Inc. (DXCM)?
- The earnings per share (EPS) for DXCM stock is 2.34.
- Is DexCom, Inc.'s earnings per share (EPS) high or low?
- DexCom, Inc.'s earnings per share (EPS) of 2.34 is 80% above its 5-year average of 1.30, near the high end of its 5-year range (0.56–2.34).
- What is the TTM average earnings per share (EPS) for DexCom, Inc. (DXCM)?
- The TTM average earnings per share (EPS) for DXCM stock is 1.80.
- What is the 3Y average earnings per share (EPS) for DexCom, Inc. (DXCM)?
- The 3Y average earnings per share (EPS) for DXCM stock is 1.48.
- What is the 5Y average earnings per share (EPS) for DexCom, Inc. (DXCM)?
- The 5Y average earnings per share (EPS) for DXCM stock is 1.30.
- What is the 10Y average earnings per share (EPS) for DexCom, Inc. (DXCM)?
- The 10Y average earnings per share (EPS) for DXCM stock is 0.65.
- What is the 15Y average earnings per share (EPS) for DexCom, Inc. (DXCM)?
- The 15Y average earnings per share (EPS) for DXCM stock is 0.40.
- What is the 20Y average earnings per share (EPS) for DexCom, Inc. (DXCM)?
- The 20Y average earnings per share (EPS) for DXCM stock is 0.11.
DexCom, Inc. Earnings Per Share (EPS) History
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | 2.14 |
| 2024-12-31 | 1.46 |
| 2023-12-31 | 1.44 |
| 2022-12-31 | 0.88 |
| 2021-12-31 | 0.56 |
| 2020-12-31 | 1.31 |
| 2019-12-31 | 0.28 |
| 2018-12-31 | -0.36 |
| 2017-12-31 | -0.15 |
| 2016-12-31 | -0.20 |
| 2015-12-31 | -0.18 |
| 2014-12-31 | -0.07 |
| 2013-12-31 | -0.10 |
| 2012-12-31 | -0.20 |
| 2011-12-31 | -0.17 |
| 2010-12-31 | -0.24 |
| 2009-12-31 | -0.30 |
| 2008-12-31 | -0.47 |
| 2007-12-31 | -0.41 |
| 2006-12-31 | -0.43 |
| 2005-12-31 | -0.41 |
| 2004-12-31 | -1.53 |
| 2003-12-31 | -1.14 |
| 2002-12-31 | -0.94 |
| 2001-12-31 | -0.83 |
| 2000-12-31 | -0.57 |
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach